- For Print
- February 2, 2016
Listed Company Name:Eisai Co., Ltd.
Officer and CEO
Stock Exchange Listings:First Section of the Tokyo
Vice President, Corporate Affairs
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) announced today that based on recent trends in business results, etc., the company has revised its full-year consolidated financial results forecasts for the fiscal year ending March 31, 2016 (April 1, 2015 to March 31, 2016) previously announced on May 14, 2015, as follows:
1. Revised full-year consolidated financial results forecasts for the fiscal year ending March 31, 2016 (April 1, 2015 to March 31, 2016)
(Unit: Millions of yen, unless otherwise noted.)
*You can scroll to the left or right here
|Previously announced forecast (A)
(May 14, 2015)
|Currently revised forecast (B)||556,500||51,000||49,000||37,000||129.00 yen|
|Change in amount (B - A)||-||5,000||6,200||10,000|
|Percentage of change (%)||-%||10.9%||14.5%||37.0%|
|(Reference) Business results for the fiscal year ended March 31, 2015||548,465||28,338||25,875||43,453||151.57 yen|
2. Reason for revision of the consolidated financial results forecasts
Due to the high growth of global brands including Halaven, Lenvima and Fycompa, the revenue forecast remains unchanged from the previous forecast of ¥556,500 million (up 1.5% from the previous fiscal year).
Gross profit is forecasted to increase from the previous fiscal year due to increased revenue from the pharmaceutical business. In addition, together with taking measures to improve cost efficiency, Eisai expects gains on sales of investments in subsidiaries as well as non-current assets and has received upfront payments under joint development and promotion agreements toward further streamlining and concentration of the business. As a result, operating profit is forecasted to be ¥51,000 million (up ¥5,000 million from the previous forecast).
Profit for the period is forecasted to be ¥37,000 million (up ¥10,000 million from the previous forecast), attributable to an increase in operating profit as well as a decline in tax expenses mainly due to transfer price adjustment between Japan and the United States. Furthermore, the forecast for the total dividend for the year remains unchanged at ¥150 per share (same amount as the previous fiscal year).